Page 346 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

324 PART III Therapeutic Modalities for the Cancer Patient

209. Acosta ADP, Gomar C, Correa-Natalini C, et al.: Analgesic effects 229. Brown DC, Iadarola MJ, Perkowski SZ, et al.: Physiologic and
of epidurally administered levogyral ketamine alone or in combi- antinociceptive effects of intrathecal resiniferatoxin in a canine
nation with morphine on intraoperative and postoperative pain bone cancer model, Anesthesiology 103:1052–1059, 2005.
VetBooks.ir in dogs undergoing ovariohysterectomy, Am J Vet Res 66:54–61, 230. Brown DC, Agnello K: Intrathecal substance P-saporin in the
2005.
dog: efficacy in bone cancer pain, Anesthesiology 19:1178–1185,
210. Sarrau S, Jourdan J, Dupuis-Soyris F, et al.: Effects of postoperative
2013.
ketamine infusion on pain control and feeding behaviour in bitches 231. Sapio MR, Neubert JK, Lapaglia DM, et al.: Pain control through
undergoing mastectomy, J Small Anim Pract 48:670–676, 2007. selective chemo-axotomy of centrally projecting TRPV1+ sensory
211. Kongara K, Chambers JP, Johnson CB: Effects of tramadol, mor- neurons, J Clin Invest 128:1657–1670, 2018.
phine or their combination in dogs undergoing ovariohysterectomy 232. Lewin GR, Ritter AM, Mendell LM: Nerve growth factor-induced
on peri-operative electroencephalographic responses and post- hyperalgesia in the neonatal and adult rat, J Neurosci 13:2136–
operative pain, NZ Vet J 60:129–135, 2012. 2148, 1993.
212. Kalchofner Guerrero KS, Reichler IM, Schwarz A, et al.: Alfaxalone 233. Lane NE, Schnitzer TJ, Birbara CA, et al.: Tanezumab for the
or ketamine-medetomidine in cats undergoing ovariohysterectomy: treatment of pain from osteoarthritis of the knee, N Engl J Med
a comparison of intra-operative parameters and post-operative 363:1521–1531, 2010.
pain, Vet Anaesth Analg 41:644–653, 2014. 234. Sanga P, Katz N, Polverejan E, et al.: Efficacy, safety, and toler-
213. Crociolli GC, Cassu RN, Barbero RC, et al.: Gabapentin as an ability of fulranumab, an anti-nerve growth factor antibody, in the
adjuvant for postoperative pain management in dogs undergoing treatment of patients with moderate to severe osteoarthritis pain,
mastectomy, J Vet Med Sci 77:1011–1015, 2015. Pain 154:1910–1919, 2013.
214. Gutierrez-Blanco E, Victoria-Mora JM, Ibancovichi-Camarillo 235. Bannwarth B, Kostine M: Biologics in the treatment of chronic
JA, et al.: Postoperative analgesic effects of either a constant rate pain: a new era of therapy? Clin Pharmacol Ther 97:122–124, 2015.
infusion of fentanyl, lidocaine, ketamine, dexmedetomidine, or the 236. Malfait AM, Miller RJ: Emerging targets for the management of
combination lidocaine-ketamine-dexmedetomidine after ovario- osteoarthritis pain, Curr Osteoporos Rep 14:260–268, 2016.
hysterectomy in dogs, Vet Anaesth Analg 42:309–318, 2015. 237. Malik-Hall M, Dina OA, Levine JD: Primary afferent nociceptor
215. Culp LB, Skarda RT, Muir WW: Comparisons of the effects of mechanisms mediating NGF-induced mechanical hyperalgesia,
acupuncture, electroacupuncture, and transcutaneous cranial elec- Eur J Neurosci 21:3387–3394, 2005.
trical stimulation on the minimum alveolar concentration of isoflu- 238. Cirillo G, Cavaliere C, Bianco MR, et al.: Intrathecal NGF admin-
rane in dogs, Am J Vet Res 66:1364–1370, 2005. istration reduces reactive astrocytosis and changes neurotrophin
216. Zhang RX, Li A, Liu B, et al.: Electroacupuncture attenuates bone receptors expression pattern in a rat model of neuropathic pain,
cancer pain and inhibits spinal interleukin-1β expression in a rat Cell Mol Neurobiol 30:51–62, 2010.
model, Anesth Analg 105:1482–1488, 2007. 239. Eibl JK, Strasser BC, Ross GM: Structural, biological, and pharma-
217. Zhang RX, Li A, Liu B, et al.: Electroacupuncture attenuates bone cological strategies for the inhibition of nerve growth factor, Neuro-
cancer-induced hyperalgesia and inhibits spinal preprodynorphin chem Int 61:1266–1275, 2012.
expression in a rat model, Eur J Pain 12:870–878, 2008. 240. Schnitzer TJ, Marks JA: A systematic review of the efficacy and gen-
218. Mantyh PW: Neurobiology of substance P and the NK1 receptor, eral safety of antibodies to NGF in the treatment of osteoarthritis
J Clin Psychiatry 63:6–10, 2002. of the hip or knee, Osteoarthr Cartil 23:S8–S17, 2015.
219. Wiley RGLDA: Targeted toxins in pain, Adv Drug Deliv Rev 241. Kryger GS, Kryger Z, Zhang F, et al.: Nerve growth factor inhibi-
55:1043–1054, 2003. tion prevents traumatic neuroma formation in the rat, J Hand Surg
220. Wiley RG, Kline IVRH, Vierck CJ: Anti-nociceptive effects of Am 26:635–644, 2001.
selectively destroying substance P receptor-expressing dorsal horn 242. Jimenez-Andrade JM, Ghilardi JR, Castañeda-Corral G, et al.:
neurons using [Sar9,Met(O2)11]-substance P-saporin: behavioral Preventive or late administration of anti-NGF therapy attenuates
and anatomical analyses, Neuroscience 146:1333–1345, 2007. tumor-induced nerve sprouting, neuroma formation, and cancer
221. Wiley RG: Substance P receptor-expressing dorsal horn neurons: pain, Pain 152:2564–2574, 2011.
lessons from the targeted cytotoxin, substance P-saporin, Pain 243. Miller RE, Block JA, Malfait AM: Nerve growth factor blockade
136:7–10, 2008. for the management of osteoarthritis pain, Curr Opin Rheumatol
222. Allen JW, Horais KA, Tozier NA, et al.: Intrathecal substance 29:110–118, 2017.
P-saporin selectively lesions NK-1 receptor bearing neurons in 244. Schnitzer TJ, Ekman EF, Spierings ELH, et al.: Efficacy and safety
dogs, J Pain 3:51, 2002. of tanezumab monotherapy or combined with non-steroidal anti-
223. Brown DC, Agnello K, Iadarola MJ: Intrathecal resiniferatoxin in inflammatory drugs in the treatment of knee or hip osteoarthritis
a dog model: efficacy in bone cancer pain, Pain 156:1018–1024, pain, Ann Rheum Dis 74:1202–1211, 2015.
2015. 245. Shor S, Fadl-Alla BA, Pondenis HC, et al.: Expression of nocicep-
224. Nymeyer H, Lappi DA, Higgins D, et al.: Substance P–saporin tive ligands in canine osteosarcoma, J Vet Intern Med 29:268–275,
for the treatment of intractable pain. In Grawunder UBS, editor: 2015.
milestones in drug therapy, Cham, 2017, Springer, pp 107–130. 246. Koppenol WH, Bounds PL, Dang CV: Otto Warburg’s contribu-
225. Huang ZJ, Li HC, Cowan AA, et al.: Chronic compression or acute tions to current concepts of cancer metabolism, Nat Rev 11:325–
dissociation of dorsal root ganglion induces cAMP-dependent neuro- 337, 2011.
nal hyperexcitability through activation of PAR2, Pain 153:1426– 247. Cairns RA, Harris IS, Mak TW: Regulation of cancer cell metabo-
1437, 2012. lism, Nat Rev 11:85–95, 2011.
226. Serrano A, Paré M, McIntosh F, et al.: Blocking spinal CCR2 with 248. Walenta S, Schroeder T, Mueller-Klieser W: Lactate in solid malig-
AZ889 reversed hyperalgesia in a model of neuropathic pain, Mol nant tumors: potential basis of a metabolic classification in clinical
Pain 6:1–14, 2010. oncology, Curr Med Chem 11:2195–2204, 2004.
227. Stevens R, Hanson P, Wei N, et al.: Safety and tolerability of 249. Vaupel P: Metabolic microenvironment of tumor cells: a key factor
CNTX-4975 in subjects with chronic, moderate to severe knee in malignant progression, Exp Oncol 32:125–127, 2010.
pain associated with osteoarthritis: a pilot study, J Pain 18:S70, 250. Ogilvie GK, Vail DM: Nutrition and cancer - recent developments,
2017. Vet Clin North Am Small Anim Pract 20:969–985, 1990.
228. Karai L, Brown DC, Mannes AJ, et al.: Deletion of vanilloid recep- 251. Ogilvie GK, Vail DM, Wheeler SL, et al.: Effects of chemotherapy
tor 1–expressing primary afferent neurons for pain control, J Clin and remission on carbohydrate metabolism in dogs with lym-
Invest 113:1344–1352, 2004. phoma, Cancer 69:233–238, 1992.